Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

SECTION 1.2

Description of the concentration

1.On 14 September 2021, the Commission received a notification for the acquisition of sole control within the meaning of Article 3(1)(b) of Council Regulation (EC) No 139/2004 (the “EU Merger Regulation”) of Swedish Orphan Biovitrum (“Sobi”) by funds managed and/or advised by Advent International Corporation and/or its affiliates (“Advent”). This transaction constitutes a notifiable concentration within the EU Merger Regulation.

2.Advent is a private equity investor based in Boston, USA. Advent focuses on the acquisition of equity stakes and the management of investment funds in various sectors, including healthcare, industrial, technology, retail, consumer and leisure, and business and financial services.

3.Sobi is headquartered in Stockholm, Sweden and is listed on the Nasdaq Stockholm stock exchange. Sobi is an originator pharmaceutical company focussing on the treatment of rare diseases, with its principal areas of focus on treatments in haematology and immunology.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.